Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

TOLLIP , MUC5B , and the Response to N -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis

Open access
Oldham, Justin M., Ma, Shwu-Fan, Martinez, Fernando J., Anstrom, Kevin J., Raghu, Ganesh, Schwartz, David A., Valenzi, Eleanor, Witt, Leah, Lee, Cathryn, Vij, Rekha, Huang, Yong, Strek, Mary E., Noth, Imre · 2015 · American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology. The genes TOLLIP and MUC5B play important roles in lung host defense, which is an immune process influenced by oxidative signaling. Whether polymorphisms in TOLLIP and MUC5B modify the effect of immunosuppressive and antioxidant therapy in individuals with IPF is unknown. Objectives: To determine whether single-nucleotide polymorphisms (SNPs) within TOLLIP and MUC5B modify the effect of interventions in subjects participating in the Evaluating the Effectiveness of Prednisone, Azathioprine, and N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis (PANTHER-IPF) clinical trial. Methods: SNPs within TOLLIP (rs5743890/rs5743894/rs5743854/rs3750920) and MUC5B (rs35705950) were genotyped. Interaction modeling was conducted with multivariable Cox regression followed by genotype-stratified survival analysis using a composite endpoint of death, transplantation, hospitalization, or a decline of ≥10% in FVC. Measurements and Main Results: Significant interaction was observed between N-acetylcysteine (NAC) therapy and rs3750920 within TOLLIP (Pinteraction = 0.001). After stratifying by rs3750920 genotype, NAC therapy was associated with a significant reduction in composite endpoint risk (hazard ratio, 0.14; 95% confidence interval, 0.02–0.83; P = 0.03) in those with a TT genotype, but a nonsignificant increase in composite endpoint risk (hazard ratio, 3.23; 95% confidence interval, 0.79–13.16; P = 0.10) was seen in those with a CC genotype. These findings were then replicated in an independent IPF cohort. Conclusions: NAC may be an efficacious therapy for individuals with IPF with an rs3750920 (TOLLIP) TT genotype, but it was associated with a trend toward harm in those with a CC genotype. A genotype-stratified prospective clinical trial should be conducted before any recommendation regarding the use of off-label NAC to treat IPF.

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.201505-1010oc

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. Oldham, 2015, Genetic heterogeneity among patients enrolled in the PANTHER-IPF clinical trial [abstract], Am J Respir Crit Care Med, 191, A2162

Cited by

See all 353

Metadata

Authors
Oldham, J. M., Ma, S.-F., Martinez, F. J., Anstrom, K. J., Raghu, G., Schwartz, D. A., Valenzi, E., Witt, L., Lee, C., Vij, R., Huang, Y., Strek, M. E., & Noth, I.
Affiliations
  • University of Chicago (US)
  • Department of Internal Medicine, Weill Cornell Medical School, New York City, New York
  • Duke University (US)
  • University of Washington Medical Center (US)
  • University of Colorado Denver (US)
Corresponding author
Oldham, Justin M.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2015-12
Volume
192
Issue
12
Pages
1475-1482
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W1920916096
Cited by
341
References
38
Citations by year
2026: 13 · 2025: 21 · 2024: 46 · 2023: 30 · 2022: 34 · 2021: 32 · 2020: 40 · 2019: 29 · 2018: 25 · 2017: 33 · 2016: 34 · 2015: 3
FWCI
25.08
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
Balbach family, together with National Institutes of Health (U10 HL080513, T32 HL007605)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
idiopathic pulmonary fibrosis, Tollip, MUC5B, N-acetylcysteine, single nucleotide polymorphisms, gene-environment interaction, antioxidant therapy, immunosuppressive therapy, prednisone, azathioprine, lung function decline, oxidative stress, lung transplantation
MeSH terms
Acetylcysteine, Aged, Female, Humans, Male, Risk, Cohort Studies, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Intracellular Signaling Peptides and Proteins, Idiopathic Pulmonary Fibrosis, Mucin-5B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TOLLIP , MUC5B , and the Response to N -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.201505-1010oc
The paper
Oldham, J. M., Ma, S.-F., Martinez, F. J., Anstrom, K. J., Raghu, G., Schwartz, D. A., Valenzi, E., Witt, L., Lee, C., Vij, R., Huang, Y., Strek, M. E., & Noth, I. (2015). TOLLIP , MUC5B , and the Response to N -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201505-1010oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.